Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment (Q39352989)

11 September 2017

title

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment (English)

1 reference

11 September 2017

15

1 reference

11 September 2017

14

M Bendszus

1 reference

11 September 2017

16

W Wick

1 reference

11 September 2017

11

Stephanie E. Combs

1 reference

11 September 2017

M Weiler

1

1 reference

11 September 2017

P-N Pfenning

2

1 reference

11 September 2017

A-L Thiepold

3

1 reference

11 September 2017

J Blaes

4

1 reference

11 September 2017

L Jestaedt

5

1 reference

11 September 2017

J Gronych

6

1 reference

11 September 2017

L M Dittmann

7

1 reference

11 September 2017

B Berger

8

1 reference

11 September 2017

M Jugold

9

1 reference

11 September 2017

M Kosch

10

1 reference

11 September 2017

A von Deimling

12

1 reference

11 September 2017

M Weller

13

1 reference

11 September 2017

language of work or name

English

0 references

publication date

7 May 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

32

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

1099-1109

1 reference

Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Characterization of a Spontaneous Murine Astrocytoma and Abrogation of Its Tumorigenicity by Cytokine Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

R4 RGS proteins: regulation of G-protein signaling and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Regulator of G-protein signaling (RGS) proteins in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

G protein-coupled receptors stimulation and the control of cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

The regulator of G protein signaling family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Regional expression of RGS4 mRNA in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

A role of RGS proteins in drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

A new method for the rapid and long term growth of human neural precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Gene Expression Omnibus: NCBI gene expression and hybridization array data repository

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

The pharmacology of mTOR inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.137

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.137

1 reference

11 September 2017

1 reference